Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Thursday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) therapy.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal action date of 14 November 2026.
Summit's BLA submission is based on results from the global Phase III HARMONi study, which compared ivonescimab plus platinum-doublet chemotherapy with placebo plus platinum-doublet chemotherapy in previously TKI-treated patients. Over 14,000 patients in the United States are eligible for treatment in this setting, highlighting the significant unmet medical need addressed by ivonescimab.
The FDA plans to conduct a complete review following Good Review Management Principles, including mid-cycle and wrap-up meetings, and will propose labelling subject to the review outcome.
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
United Therapeutics reports positive phase 1 data for bioengineered liver in acute liver failure